AU2002362459B2 - Methods of inhibiting metastases - Google Patents

Methods of inhibiting metastases Download PDF

Info

Publication number
AU2002362459B2
AU2002362459B2 AU2002362459A AU2002362459A AU2002362459B2 AU 2002362459 B2 AU2002362459 B2 AU 2002362459B2 AU 2002362459 A AU2002362459 A AU 2002362459A AU 2002362459 A AU2002362459 A AU 2002362459A AU 2002362459 B2 AU2002362459 B2 AU 2002362459B2
Authority
AU
Australia
Prior art keywords
tumor
taurolidine
liver
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002362459A
Other languages
English (en)
Other versions
AU2002362459A1 (en
Inventor
Rolf I Carlson
Paul Maggio
Jack R Wands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geistlich Pharma AG
Original Assignee
Geistlich Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma AG filed Critical Geistlich Pharma AG
Publication of AU2002362459A1 publication Critical patent/AU2002362459A1/en
Application granted granted Critical
Publication of AU2002362459B2 publication Critical patent/AU2002362459B2/en
Assigned to GEISTLICH PHARMA AG reassignment GEISTLICH PHARMA AG Request for Assignment Assignors: RHODE ISLAND HOSPITAL, A LIFESPAN PARTNER
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002362459A 2001-10-01 2002-10-01 Methods of inhibiting metastases Ceased AU2002362459B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32628801P 2001-10-01 2001-10-01
US60/326,288 2001-10-01
PCT/US2002/031079 WO2003028642A2 (en) 2001-10-01 2002-10-01 Methods of inhibiting metastases

Publications (2)

Publication Number Publication Date
AU2002362459A1 AU2002362459A1 (en) 2003-06-26
AU2002362459B2 true AU2002362459B2 (en) 2007-08-02

Family

ID=23271590

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002362459A Ceased AU2002362459B2 (en) 2001-10-01 2002-10-01 Methods of inhibiting metastases

Country Status (6)

Country Link
US (2) US6753328B2 (enExample)
EP (1) EP1450814B1 (enExample)
JP (2) JP5280603B2 (enExample)
AU (1) AU2002362459B2 (enExample)
CA (1) CA2462564C (enExample)
WO (1) WO2003028642A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753328B2 (en) * 2001-10-01 2004-06-22 Rhode Island Hospital Methods of inhibiting metastases
WO2004094823A2 (en) 2003-04-23 2004-11-04 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
JP2009532117A (ja) 2006-03-30 2009-09-10 ヴァレリタス，エルエルシー マルチカートリッジ式流体投与装置
CN101528195B (zh) * 2006-09-07 2012-03-28 埃德盖斯特利希索恩化学工业股份公司 羟甲基转移剂在制备治疗骨癌的药物中的用途
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2011011688A2 (en) 2009-07-24 2011-01-27 Rhode Island Hospital DENDRITIC CELL VACCINES FOR ASPARAGINYL- β - HYDROXYLASE EXPRESSING TUMORS
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124285A (en) 1964-10-06 1968-08-21 Geistlich Soehne Ag Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them
GB1408010A (en) 1972-11-20 1975-10-01 Geistlich Soehne Ag Sulphamoylphenyl-imidazolidinones
GB1557163A (en) 1975-06-24 1979-12-05 Geistlich Soehne Ag Dental care preparations
US4107305A (en) 1975-08-04 1978-08-15 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of endotoxaemia
GB1588110A (en) 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4337251A (en) 1979-05-09 1982-06-29 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of avoiding and removing adhesions
CA1190855A (en) 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
GB8328073D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328111D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328074D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compositions
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5573771A (en) 1988-08-19 1996-11-12 Osteomedical Limited Medicinal bone mineral products
US5069662A (en) * 1988-10-21 1991-12-03 Delcath Systems, Inc. Cancer treatment
US5819748A (en) 1988-11-30 1998-10-13 Ed Geistlich Sohne Ag Fur Chemische Industrie Implant for use in bone surgery
GB8827986D0 (en) 1988-11-30 1989-01-05 Geistlich Soehne Ag Chemical product
GB9005856D0 (en) 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
GB9216155D0 (en) 1992-07-30 1992-09-09 Geistlich Soehne Ag Treatment of dentoalveolar infections
US5954687A (en) 1995-04-28 1999-09-21 Medtronic, Inc. Burr hole ring with catheter for use as an injection port
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
GB9600426D0 (en) 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
AU734460B2 (en) 1997-05-22 2001-06-14 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6011030A (en) 1997-09-22 2000-01-04 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating symptoms of microbial infection or sepsis
US5972933A (en) 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6117868A (en) 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
SE516215C2 (sv) * 1999-07-10 2001-12-03 Argmed Kb Perfusionssystem samt pumpanordning och styrsystem för användning i perfusionssystemet
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US6753328B2 (en) * 2001-10-01 2004-06-22 Rhode Island Hospital Methods of inhibiting metastases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors

Also Published As

Publication number Publication date
WO2003028642A2 (en) 2003-04-10
US20050032785A1 (en) 2005-02-10
US6753328B2 (en) 2004-06-22
JP5280603B2 (ja) 2013-09-04
EP1450814A2 (en) 2004-09-01
CA2462564C (en) 2012-07-10
JP2010209101A (ja) 2010-09-24
JP2005504814A (ja) 2005-02-17
WO2003028642A3 (en) 2003-12-04
US20030069229A1 (en) 2003-04-10
CA2462564A1 (en) 2003-04-10
WO2003028642A9 (en) 2004-03-04
US7122541B2 (en) 2006-10-17
EP1450814B1 (en) 2016-11-30
EP1450814A4 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
US10245240B2 (en) Treatment of prostate carcinoma
US6469061B1 (en) Jasmonate pharmaceutical composition for treatment of cancer
US6482802B1 (en) Use of neomycin for treating angiogenesis-related diseases
RU2161487C2 (ru) Применение производных 2-гидрокси-5-фенилазобензойной кислоты в качестве химиопрофилактических и химиотерапевтических агентов при раке ободочной кишки
JP2010209101A (ja) 転移阻害のための方法
Yousef et al. The potential protective role of taurine against 5-fluorouracil-induced nephrotoxicity in adult male rats
JP2002509884A (ja) 癌の化学防御におけるｄｆｍｏ及びスリンダクの組合せ
Rubin et al. Cyclophosphamide hemorrhagic cystitis
EP2034835A2 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
Sugarbaker A perspective on clinical research strategies in carcinoma of the large bowel
US20030036539A1 (en) Use of 2-ME in promotion of apoptosis in the prevention of initial onset and recurrence of existing cancers
AU2002362459A1 (en) Methods of inhibiting metastases
Leach et al. Influence of chloroquine on diet-induced pancreatitis
Alvarez Carcinoma of the main hepatic ducts, within the liver: a report of two cases, treated by intrahepatic cholangiojejunostomy
CN120771164A (zh) 双硫死亡抑制剂在药物中的应用及药物
Hadjiminas et al. Asymptomatic metastatic small bowel carcinoid
Beland Comparison of total androgen blockade and orchiectomy in metastatic cancer of prostate
Keller et al. 13C-MIXED TRIGLYCERIDE BREATH TEST (13C-MTG) DEMONSTRATES SUPERIORITY OF ENTERIC COATED MONOLITHIC ENZYME PREPARATION OVER PLACEBO: A MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL
Okaro Anti-apoptotic proteins and cholangiocarcinoma
Kettlewell Neoplasms: present surgical treatment
Murphy et al. Bile and fatty acid ethyl ester cause necrosis of pancreatic acinar cells by potentiation of second messenger receptor calcium release
Ohno et al. Rottlerin stimulates apoptosis in pancreatic cancer through inhibition of Bcl-xL
Pagar A Study on Anti-Ulcer and Hepatoprotective Activity and Correlation with Anti-Oxidant Activity of Leaves of Portuleca Oleracea Linn
JP2012072077A (ja) 子宮筋腫細胞増殖抑制剤
WO2008123759A1 (es) N-sulfoetilnicotinamida, composiciones farmacéuticas que la contienen y uso de las mismas para inhibir o evitar la formación no deseada de tejido fibroso

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GEISTLICH PHARMA AG

Free format text: FORMER OWNER WAS: RHODE ISLAND HOSPITAL, A LIFESPAN PARTNER

MK14 Patent ceased section 143(a) (annual fees not paid) or expired